These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34579229)

  • 1. Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.
    Maharjan PM; Choe S
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
    Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
    Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
    Ward BJ; Gobeil P; Séguin A; Atkins J; Boulay I; Charbonneau PY; Couture M; D'Aoust MA; Dhaliwall J; Finkle C; Hager K; Mahmood A; Makarkov A; Cheng MP; Pillet S; Schimke P; St-Martin S; Trépanier S; Landry N
    Nat Med; 2021 Jun; 27(6):1071-1078. PubMed ID: 34007070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
    Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
    J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.
    Charland N; Gobeil P; Pillet S; Boulay I; Séguin A; Makarkov A; Heizer G; Bhutada K; Mahmood A; Trépanier S; Hager K; Jiang-Wright J; Atkins J; Saxena P; Cheng MP; Vinh DC; Boutet P; Roman F; Van Der Most R; Ceregido MA; Dionne M; Tellier G; Gauthier JS; Essink B; Libman M; Haffizulla J; Fréchette A; D'Aoust MA; Landry N; Ward BJ
    NPJ Vaccines; 2022 Nov; 7(1):142. PubMed ID: 36351931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19.
    Dubé C; Paris-Robidas S; Primakova I; Destexhe E; Ward BJ; Landry N; Trépanier S
    Reprod Toxicol; 2022 Jan; 107():69-80. PubMed ID: 34838689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    O'Kennedy MM; Abolnik C; Smith T; Motlou T; Goosen K; Sepotokele KM; Roth R; du Preez I; Truyts A; Stark HC; Magwaza M; Mahanjana O; Verschoor JA; Moore PL; Lemmer Y
    Vaccine; 2023 Mar; 41(13):2261-2269. PubMed ID: 36868876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in
    Mamedov T; Yuksel D; Ilgın M; Gürbüzaslan I; Gulec B; Mammadova G; Ozdarendeli A; Yetiskin H; Kaplan B; Islam Pavel ST; Uygut MA; Hasanova G
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plant-Expressed Receptor Binding Domain of the SARS-CoV-2 Spike Protein Elicits Humoral Immunity in Mice.
    Maharjan PM; Cheon J; Jung J; Kim H; Lee J; Song M; Jeong GU; Kwon Y; Shim B; Choe S
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
    Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
    Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
    Shih HI; Wu CJ; Tu YF; Chi CY
    Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
    Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants.
    Mamedov T; Yuksel D; Gurbuzaslan I; Ilgin M; Gulec B; Mammadova G; Ozdarendeli A; Pavel STI; Yetiskin H; Kaplan B; Uygut MA; Hasanova G
    Front Plant Sci; 2023; 14():1202570. PubMed ID: 37600182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
    Geng Q; Tai W; Baxter VK; Shi J; Wan Y; Zhang X; Montgomery SA; Taft-Benz SA; Anderson EJ; Knight AC; Dinnon KH; Leist SR; Baric RS; Shang J; Hong SW; Drelich A; Tseng CK; Jenkins M; Heise M; Du L; Li F
    PLoS Pathog; 2021 Sep; 17(9):e1009897. PubMed ID: 34492082
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.